Ian W. Flinn, MD, PhD | Authors


Polatuzumab Shows Improved Survival and Complete Responses in R/R DLBCL

July 06, 2022

Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

Cerdulatinib in Relapsed/Refractory B-Cell Malignancies

June 03, 2015

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.

Two Ongoing Clinical Trials of IPI-145 for Hematologic Malignancies

June 05, 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.